Holen Sie sich die Stockscreener-App
48.46
0.59%
-0.29
Schlusskurs vom Vortag:
$48.75
Offen:
$48.8
24-Stunden-Volumen:
1.13M
Relative Volume:
1.52
Marktkapitalisierung:
$2.81B
Einnahmen:
$776.83M
Nettoeinkommen (Verlust:
$-29.02M
KGV:
-94.65
EPS:
-0.512
Netto-Cashflow:
$82.25M
1W Leistung:
+0.85%
1M Leistung:
+7.47%
6M Leistung:
-5.18%
1J Leistung:
+46.23%
1-Tages-Spanne:
$47.39
$48.80
1-Wochen-Bereich:
$46.76
$51.37
52-Wochen-Spanne:
$32.20
$59.68
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Firmenname
Supernus Pharmaceuticals Inc
Sektor
Telefon
301-838-2500
Adresse
9715 KEY WEST AVENUE, ROCKVILLE, MD
Compare SUPN vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
48.46 | 2.81B | 776.83M | -29.02M | 82.25M | -0.512 |
TAK
Takeda Pharmaceutical Co Adr
|
16.56 | 52.88B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.76 | 42.98B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.95 | 38.37B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
75.56 | 31.68B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
547.06 | 23.22B | 3.17B | 1.29B | 1.01B | 27.09 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-09 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-07-30 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-02-19 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-09-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-01-03 | Fortgesetzt | Jefferies | Buy |
| 2021-12-01 | Fortgesetzt | Jefferies | Buy |
| 2021-04-13 | Hochstufung | Jefferies | Hold → Buy |
| 2020-06-16 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-06-15 | Fortgesetzt | Jefferies | Hold |
| 2019-11-08 | Herabstufung | Berenberg | Buy → Hold |
| 2019-11-07 | Herabstufung | Stifel | Buy → Hold |
| 2019-11-06 | Herabstufung | Jefferies | Buy → Hold |
| 2018-11-12 | Bestätigt | B. Riley FBR | Buy |
| 2018-01-18 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-12-28 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-12-04 | Hochstufung | Janney | Neutral → Buy |
| 2017-11-08 | Hochstufung | Stifel | Hold → Buy |
| 2017-10-19 | Eingeleitet | FBR & Co. | Buy |
| 2017-09-19 | Herabstufung | Stifel | Buy → Hold |
| 2017-07-17 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-07-14 | Eingeleitet | Janney | Neutral |
| 2017-06-01 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-07-18 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2016-07-18 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2016-02-08 | Hochstufung | Jefferies | Hold → Buy |
| 2015-11-05 | Bestätigt | Northland Capital | Outperform |
| 2015-10-28 | Eingeleitet | Northland Capital | Outperform |
Alle ansehen
Supernus Pharmaceuticals Inc Aktie (SUPN) Neueste Nachrichten
Avoiding Lag: Real-Time Signals in (SUPN) Movement - Stock Traders Daily
SUPN Maintained by Cantor Fitzgerald -- Price Target Raised to $67.00 - GuruFocus
Strength Seen in Supernus (SUPN): Can Its 5.2% Jump Turn into More Strength? - Yahoo Finance UK
Britannia, US WorldMeds, Supernus move for judgment in US antitrust case on Apokyn - MLex
Jack Khattar: Innovator, Business Leader, and Founder, President and CEO of Supernus Pharmaceuticals - BBN Times
Enterprise value to EBITDA forward of Supernus Pharmaceuticals, Inc. – NASDAQ:SUPN - TradingView
Enterprise value to EBITDA forward of Supernus Pharmaceuticals, Inc. – BX:S49 - TradingView
Enterprise value to EBITDA forward of Supernus Pharmaceuticals, Inc. – DUS:S49 - TradingView
Price to sales forward of Supernus Pharmaceuticals, Inc. – NASDAQ:SUPN - TradingView
Supernus Pharmaceuticals (SUPN) Following Shelf Filing Has Its Undervalued Case In Focus - Sahm
Price to sales forward of Supernus Pharmaceuticals, Inc. – FWB:S49 - TradingView
Discipline and Rules-Based Execution in SUPN Response - Stock Traders Daily
SUPN Q1 2026 Earnings: EPS Surges 97.69% Above EstimatesEarnings Sentiment Score - dars.gov.et
Price to book forward of Supernus Pharmaceuticals, Inc. – NASDAQ:SUPN - TradingView
Enterprise value to EBIT forward of Supernus Pharmaceuticals, Inc. – NASDAQ:SUPN - TradingView
Enterprise value to EBIT forward of Supernus Pharmaceuticals, Inc. – LSE:0LB2 - TradingView
Q3 2025 Supernus Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Supernus Pharmaceuticals, Inc. Actuals & Estimates (BX:S49) - TradingView
Price to earnings forward of Supernus Pharmaceuticals, Inc. – NASDAQ:SUPN - TradingView
Supernus Pharmaceuticals, Inc. Actuals & Estimates (LSE:0LB2) - TradingView
S49 Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBITDA forward of Supernus Pharmaceuticals, Inc. – LSE:0LB2 - TradingView
SUPN Forecast — Price Target — Prediction for 2027 - TradingView
Supernus Pharmaceuticals, Inc. Actuals & Estimates (LSX:A1JX3U) - TradingView
0LB2 Forecast — Price Target — Prediction for 2027 - TradingView
A1JX3U Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of Supernus Pharmaceuticals, Inc. – LSE:0LB2 - TradingView
Price to earnings forward of Supernus Pharmaceuticals, Inc. – LSE:0LB2 - TradingView
Enterprise value to revenue forward of Supernus Pharmaceuticals, Inc. – NASDAQ:SUPN - TradingView
Q4 2025 Supernus Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Supernus Pharmaceuticals Insiders Sold US$2.1m Of Shares Suggesting Hesitancy - 富途牛牛
Branded Pharmaceuticals Stocks Q1 Teardown: Supernus Pharmaceuticals (NASDAQ:SUPN) Vs The Rest - Yahoo Finance
How Strong Quarterly Results and MERGE Partnership Will Impact Supernus Pharmaceuticals (SUPN) Investors - Sahm
Supernus Investors Approve Directors, Pay and Incentive Plan - The Globe and Mail
Supernus Pharmaceuticals shareholders approve director elections and key proposals - Investing.com UK
Supernus Pharmaceuticals shareholders approve director elections and key proposals By Investing.com - Investing.com Nigeria
Supernus (NASDAQ: SUPN) holders approve directors, say-on-pay and equity plan - Stock Titan
Behavioral Patterns of SUPN and Institutional Flows - Stock Traders Daily
Supernus Pharmaceuticals Inc (SUPN) Institutional Confidence - TradingKey
Supernus Pharmaceuticals Inc (SUPN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Supernus Pharmaceuticals Inc (SUPN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Supernus Pharmaceuticals Inc (SUPN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Supernus Pharmaceuticals Inc (SUPN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Supernus Pharmaceuticals names MERGE as agency of record By Investing.com - Investing.com South Africa
Supernus Pharmaceuticals Inc (SUPN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Supernus Pharmaceuticals names MERGE as agency of record - Investing.com
Supernus Pharmaceuticals Inc - TradingKey
Supernus Expands Partnership With MERGE as AI-Powered Agency of Record - The Manila Times
Supernus Pharmaceuticals Inc (SUPN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Supernus Pharmaceuticals (SUPN) Holds Steady at Key Support: Consolidation Phase Ahead?Wave Extension - dars.gov.et
Supernus Pharmaceuticals Inc (SUPN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Finanzdaten der Supernus Pharmaceuticals Inc-Aktie (SUPN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Supernus Pharmaceuticals Inc-Aktie (SUPN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 16 '26 |
Option Exercise |
33.62 |
50,000 |
1,681,205 |
67,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 18 '26 |
Option Exercise |
39.40 |
7,250 |
285,650 |
24,294 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 17 '26 |
Sale |
50.30 |
50,000 |
2,514,886 |
17,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 16 '26 |
Sale |
50.28 |
50,000 |
2,513,925 |
17,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 18 '26 |
Sale |
49.60 |
7,250 |
359,621 |
17,044 |
3.42%
0.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):